Publications by authors named "Maria J Blanco Banares"
Article Synopsis
- Research on factors affecting deep vein thrombosis (DVT) resolution in children with central venous access devices (CVAD) is limited, impacting treatment decisions.
- A study of 85 pediatric patients found that successful thrombus resolution in the first 6 months was less likely with total occlusions, certain vein locations, early collateral circulation, and fewer prothrombotic risk factors.
- The findings indicate that these risk factors should be carefully considered for anticoagulation treatment duration and effectiveness in pediatric patients with CVAD-associated DVT.
Introduction: We present the first registry of patients with congenital bleeding disorders and COVID-19. The study has been carried out in the Community of Madrid, which has the highest number of cases in Spain. The objective is to understand the incidence of COVID-19, the course of the disease if it occurs and the psychosocial and occupational impact on this population.
View Article and Find Full Text PDFAim: To evaluate the influence of two variants of P450 oxidoreductase (POR), rs2868177 and POR*28, on the stable dosage of acenocoumarol.
Patients & Methods: For this observational, cross-sectional study, patients were undergone stable anticoagulant treatment with acenocoumarol. Univariate and multiple regression analyses were performed to assess the influence of POR polymorphisms.
Article Synopsis
- Genetic variations significantly impact how much acenocoumarol patients need, and testing for these variations can lead to better health outcomes and resource use.
- The study developed a predictive algorithm that incorporates both clinical and genetic factors to determine optimal acenocoumarol dosages, utilizing data from 685 patients across three healthcare settings.
- The algorithm showed effectiveness, with a coefficient of determination (R2) of 52.8% in the training group and 64% in the validation group, helping to classify patients into correct dosage categories more accurately.
Background: Our goal was to analyze the association of the level of antiphospholipid antibodies (aPLs) with stroke severity and outcome in patients with antiphospholipid syndrome (APS).
Methods: Observational study included consecutive patients with ischemic stroke younger than 55 years (2007-2012). We analyzed serum levels of aPLs, including anticardiolipin (aCL) antibodies, anti-β2-glycoprotein I antibodies (anti-β2GPI) and antiprothrombin antibodies (aPS/PT) within the first 48 h after admission, and again, in the case of a positive result, at least 12 weeks after the first measurement.